CN116323601B - 作为转化生长因子-β受体I/ALK5抑制剂的2-(3-吡啶-2-基-4-喹啉-4-基-吡唑-1-基)-乙酰胺衍生物 - Google Patents

作为转化生长因子-β受体I/ALK5抑制剂的2-(3-吡啶-2-基-4-喹啉-4-基-吡唑-1-基)-乙酰胺衍生物

Info

Publication number
CN116323601B
CN116323601B CN202180066883.4A CN202180066883A CN116323601B CN 116323601 B CN116323601 B CN 116323601B CN 202180066883 A CN202180066883 A CN 202180066883A CN 116323601 B CN116323601 B CN 116323601B
Authority
CN
China
Prior art keywords
pyrazol
quinolin
methylpyridin
acetamido
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180066883.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN116323601A (zh
Inventor
R·鲍瑟尔阿尔塔
B·潘平卡萨尔
J·卡斯特罗帕洛米诺拉里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agomeb Spain SA
Original Assignee
Agomeb Spain SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomeb Spain SA filed Critical Agomeb Spain SA
Publication of CN116323601A publication Critical patent/CN116323601A/zh
Application granted granted Critical
Publication of CN116323601B publication Critical patent/CN116323601B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180066883.4A 2020-09-30 2021-09-29 作为转化生长因子-β受体I/ALK5抑制剂的2-(3-吡啶-2-基-4-喹啉-4-基-吡唑-1-基)-乙酰胺衍生物 Active CN116323601B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382861.1A EP3978487A1 (en) 2020-09-30 2020-09-30 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP20382861.1 2020-09-30
PCT/EP2021/076730 WO2022069509A1 (en) 2020-09-30 2021-09-29 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (2)

Publication Number Publication Date
CN116323601A CN116323601A (zh) 2023-06-23
CN116323601B true CN116323601B (zh) 2026-05-12

Family

ID=72744716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066883.4A Active CN116323601B (zh) 2020-09-30 2021-09-29 作为转化生长因子-β受体I/ALK5抑制剂的2-(3-吡啶-2-基-4-喹啉-4-基-吡唑-1-基)-乙酰胺衍生物

Country Status (20)

Country Link
US (1) US12577230B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978487A1 (cg-RX-API-DMAC7.html)
JP (1) JP7752684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079027A (cg-RX-API-DMAC7.html)
CN (1) CN116323601B (cg-RX-API-DMAC7.html)
AR (1) AR123543A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021353965A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3196108A1 (cg-RX-API-DMAC7.html)
DK (1) DK4222149T3 (cg-RX-API-DMAC7.html)
ES (1) ES3029607T3 (cg-RX-API-DMAC7.html)
FI (1) FI4222149T3 (cg-RX-API-DMAC7.html)
IL (1) IL301663B2 (cg-RX-API-DMAC7.html)
LT (1) LT4222149T (cg-RX-API-DMAC7.html)
MX (1) MX2023002900A (cg-RX-API-DMAC7.html)
PH (1) PH12023550777A1 (cg-RX-API-DMAC7.html)
PT (1) PT4222149T (cg-RX-API-DMAC7.html)
RS (1) RS68301B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022069509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302393B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
WO2026017797A1 (en) 2024-07-17 2026-01-22 Agomab Spain S.L.U. Crystalline forms
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2009500419A (ja) * 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
IN2014CN02805A (cg-RX-API-DMAC7.html) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors;Cheng HuaJin等;《Bioorganic & Medicinal Chemistry》;20110210;第19卷;2633-2640 *
Synthesis and evaluation of the HIF-1α inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5;Yan-Wei Li等;《Bioorganic & Medicinal Chemistry Letters》;20191117;第30卷;126822(1-12) *

Also Published As

Publication number Publication date
US20230373966A1 (en) 2023-11-23
KR20230079027A (ko) 2023-06-05
FI4222149T3 (fi) 2026-07-16
MX2023002900A (es) 2023-05-25
EP4222149B1 (en) 2026-05-06
AR123543A1 (es) 2022-12-14
ES3029607T3 (es) 2026-06-23
EP4781988A2 (en) 2026-07-29
LT4222149T (lt) 2026-08-10
AU2021353965A1 (en) 2023-04-27
CN116323601A (zh) 2023-06-23
IL301663A (en) 2023-05-01
PH12023550777A1 (en) 2023-11-20
RS68301B1 (en) 2026-07-31
ES3029607T1 (en) 2025-06-24
CA3196108A1 (en) 2022-04-07
ZA202302393B (en) 2026-03-25
EP3978487A1 (en) 2022-04-06
IL301663B2 (en) 2026-05-01
WO2022069509A1 (en) 2022-04-07
PT4222149T (pt) 2026-06-03
JP2023544716A (ja) 2023-10-25
BR112023004612A2 (pt) 2023-04-11
AU2021353965A9 (en) 2024-08-01
US12577230B2 (en) 2026-03-17
EP4222149A1 (en) 2023-08-09
JP7752684B2 (ja) 2025-10-10
IL301663B1 (en) 2026-01-01
DK4222149T3 (da) 2026-07-27

Similar Documents

Publication Publication Date Title
US12577230B2 (en) 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
US10696660B2 (en) Rho kinase inhibitors
JP5905075B2 (ja) ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
EP2609091B1 (en) Pharmaceutically active compounds as axl inhibitors
JP5856673B2 (ja) 7−(3,5−ジメチル−4−イソオキサゾリル)−8−(メチルオキシ)−1H−イミダゾ[4,5−c]キノリン誘導体
US12297186B2 (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
CN107001344A (zh) 用于治疗病症的哌嗪衍生物
EA049184B1 (ru) 2-производные (3-пиридин-2-ил-4-хинолин-4-ил-пиразол-1-ил)ацетамида в качестве ингибиторов рецептора i трансформирующего фактора роста бета/alk5
JP2020521817A (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
EA045526B1 (ru) Производные бензиламида в качестве ингибиторов рецептора i/alk5 трансформирующего фактора роста-бета
HK40062730A (en) Rho kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant